



MHRA Update: International Reliance

Dr Rob Reid

Deputy Director Innovative Devices





Overview

- MHRA are proposing four new access routes for the GB market, based on device classification and type of prior approval.
- Certain devices would be eligible to undergo a streamlined review process due to reliance on assessments already performed in Australia, Canada, the EU or the USA.





How was this developed?

- Criteria for which systems are 'comparable' included similarity of population, market size and pre-market regulatory requirements
- Held regular meetings with regulators and approved bodies to gain feedback on draft policy
- Reviewed example case studies under NDA with volunteer companies

Trusted Advisor Principles:

- All meetings will be confidential, and any information shared will be kept in confidence by all members.
- Confidential dissemination of the information discussed by the Group outside of the meeting is permitted to officers, employees, advisers, subcontractors and contractors of host organisations and for Trade Associations, representatives from their wider membership organisations.
- Members will **not** use the Groups to lobby on behalf of their host organisation.





Public consultation and next steps



Consultation:
Nov 2024 –
Jan 2025



Publish response: May 2025



WTO notification: May - July 2025



Introduction of SI into parliament and debates: end of 2025



SI in force: 2026 12-month transition for IR





Further work

- Developing guidance to support the new SI
- Working with PMDA and MHLW to explore the reliance of medical device approvals from Japan
- Planning to monitor and evaluate:
 - the effectiveness of the policy in achieving its intended outcome
 - the efficiency of its implementation
 - its broader impact on the medical device sector





Thank you/Questions

Text style

- Bullet level 1 style
 - Bullet level 2 style
 - Bullet level 3 style

Subhead style